Impact of a community-based lymphedema management program on episodes of Adenolymphangitis (ADLA) and lymphedema progression--Odisha State, India

Lymphedema management programs have been shown to decrease episodes of adenolymphangitis (ADLA), but the impact on lymphedema progression and of program compliance have not been thoroughly explored. Our objectives were to determine the rate of ADLA episodes and lymphedema progression over time for p...

Full description

Saved in:
Bibliographic Details
Published in:PLoS neglected tropical diseases 2014-09, Vol.8 (9), p.e3140-e3140
Main Authors: Mues, Katherine E, Deming, Michael, Kleinbaum, David G, Budge, Philip J, Klein, Mitch, Leon, Juan S, Prakash, Aishya, Rout, Jonathan, Fox, LeAnne M
Format: Article
Language:English
Subjects:
Adult
Aged
Care and treatment
Community Health Services
Compliance
Data analysis
Development and progression
Disease control
Disease prevention
Disease Progression
Female
Humans
India - epidemiology
Influence
Lymphangitis - epidemiology
Lymphangitis - therapy
Lymphatic system
Lymphedema
Lymphedema - epidemiology
Lymphedema - therapy
Male
Medicine and Health Sciences
Middle Aged
Morbidity
Patient Compliance
Studies
Tropical diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lymphedema management programs have been shown to decrease episodes of adenolymphangitis (ADLA), but the impact on lymphedema progression and of program compliance have not been thoroughly explored. Our objectives were to determine the rate of ADLA episodes and lymphedema progression over time for patients enrolled in a community-based lymphedema management program. We explored the association between program compliance and ADLA episodes as well as lymphedema progression. A lymphedema management program was implemented in Odisha State, India from 2007-2010 by the non-governmental organization, Church's Auxiliary for Social Action, in consultation with the Centers for Disease Control and Prevention. A cohort of patients was followed over 24 months. The crude 30-day rate of ADLA episodes decreased from 0.35 episodes per person-month at baseline to 0.23 at 24 months. Over the study period, the percentage of patients who progressed to more severe lymphedema decreased (P-value  = 0.0004), while those whose lymphedema regressed increased over time (P-value
ISSN:1935-2735
1935-2727
1935-2735
DOI:10.1371/journal.pntd.0003140